PTO/SB/08 (10-01)
Approved for use through 10/31/2002. OMB 0851-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
for the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Complete If Known for form 1449A/PTO **Application Number** 10/771,931 INFORMATION DISCLOSURE Filing Date February 4, 2004 STATEMENT BY APPLICANT First Named Inventor Harry S. COURTNEY (use as many sheets as necessary) 1645 Art Unit BASKAR **Examiner Name Attorney Docket Number** of 3 13314.1001U Sheet

	U.S. PATENT DOCMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
PB	1	US-2002/0176863 A1	Nov. 28, 2002	Dale					
PB	2	US-6,619,932 B1	Jul. 169, 2002	Dale					
PB	3	US-6,063,386	May 16, 2000	Dale, et al.					
PB	4	US-4,919,930	Apr. 24, 1990	Beachey, et al.					
	5	us-							

·	FOREIGN PATENT DOCUMENTS									
	Cite No.	Foreign Patent Document Country code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	Te				
	1									
	2									
	3									

•		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
PB	1	COURTNEY, Harry S., et al.; "Serum Opacity Factor (SOF) of Streptococcus pyogenes Evokes Anitbodies that Opsonize Homologous and Heterologus SOF-Positive Serotypes of Group A Streptococci," Infection and Immunity, Vol. 71, No. 9, pp. 5097-5103 (Sept. 2003)	
PB	2	COURTNEY, Harry S., et al.; "Molecular Mechanisms of Adhesion, Colonization, and Invasion of Group A Streptococci," Annals of Medicine, Vol. 34, No. 2, pp. 77-87 (2002)	
PB	3	COURTNEY, Harry S., et al.; "Mapping the Fibrinogen-Binding Domain of Serum Opacity Factor of Group A Streptococci," Current Microbiology, Vol. 44, No. 2, pp. 236-240 (2002)	
PB	4	BRANDT, Evelyn R., et al.; "Protective and Nonprotective Epitopes from Amino Termini of M Proteins from Australian Aboriginal Isolates and Reference Strains of Group A Streptococci," Infection and Immunity, Vol. 68, No. 12, pp. 6587-6594 (December 2000)	
PB	5	CUNNINGHAM, Madeleine W.; "Pathogenesis of Group A Streptococci Infections," Clinical Microbiology Reviews, Vol. 13, No. 3, pp. 470-511 (July 2000)	
PB	6	BEALL, Bernard, et al.; "EMM and SOF Gene Sequence Variation in Relation to Serological Typing of Opacity-Factor-Positive Group A Streptococci," Microbiology, Vol. 148, pp. 1195-1209 (2000)	
PB	7	COURTNEY, Harry S., et al.; *Serum Opacity Factor is a Major Fibronectin-bBnding Protein and a Virulence Determinant of M Type 2 Streptococcus pyogenes,* Molecular Microbiology, Vol. 32, No. 1, pp. 89-98 (1999)	
PB	8	DALE, James B., et al.; "New Protective antigen of Group A Streptococci." The Journal of Clinical Investigation, Vol. 103, No. 9, pp. 1261-1268 (May 1999)	
PB	9	DALE, James B., et al.; "Recombinant, Octavalent Group A Streptococcal M Protein Vaccine," Vacine, Vol. 14, No. 10, pp. 944-948 (1996)	
PB	10	Bisno, Alan L. M.D., et al.; "Streptococcal Infections of Skin and Soft Tissues," The New England Journal of Medicine, Vol. 334, No. 4, pp. 240-245 (Jan 1996)	

Examiner	/Padmavathi Baskar/	Date Considered	07/07/2006
Signature		Considered	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

D. b. al's badanda	- 1440A (DTO :				Complete if Known	
Substitute for for				Application Number	10/771,931	
	IATION DIS			Filing Date	February 4, 2004	
STATEMENT BY APPLICANT		First Named Inventor	Harry S. COURTNEY			
	(use as many sheets a	s necessary)		Art Unit	Tous	
				Examiner Name	13 4 2 1/4 BC	
Sheet	2	of	3	Attorney Docket Number	13314.1001U	

	U.S. PATENT DOCMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	1	US-			·				
	2	US-							
	3	US-							
	4	US-							
	5	US-							

FOREIGN PATENT DOCUMENTS									
Cite No.1	Foreign Patent Document Country code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	т⁰				
 1									
 2									
3		1							

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
PB	11	KREIKEMEYER, B., et al.; "Characterization of a Novel Fibronectin-Binding surface protein in Group A Streptococci," <i>Molecular Microbiology</i> , Vol. 17, No. 1, pp. 137-145 (1995)	
PB	12	RAKONJAC, Jasna V., et al.; "DNA Sequence of the Serum Opacity Factor of Group A Streptococci: Identification of a Fibronectin-Binding Repeat Domain," Infection and Immunity, Vol. 63, No. 2, pp. 622-631 (February 1995)	
PB	13	DALE, James B., et al.; "Passive Protection of Mice Against Group A Streptococci Pharyngeal Infection by Lipoteichoic Acid," The Journal of Infectious Diseases, Vol. 169, pp. 319-323 (1994)	
PB	14	LINDGREN, Per-Eric., et al.; "Two Different Genes Coding for Fibronectin-Binding Proteins from Streptococcus Dysgalactiae," Eur. J. Biochem, Vol. 214, pp. 819-827 (1993)	
PB	15	SARAVANI, G.A., et al.; "Opacity Factor from Group A Streptococci ins an Apoproteinase," FEMS Microbiology Letters, Vol. 68, pp. 35-40 (1990)	
PB	16	FISCHETTI, Vincent A.,; "Streptococcal M Protein: Molecular Design and Biological Behavior," Clinical Microbiology Reviews, Vol. 2, No. 3 pp. 285-314 (1989)	
PB	17	DALE, James B., et al.; "Human Cytotoxic T Lymphocytes Evoked by Group A Streptococcal M Proteins," Journal of Experimental Medicine, Vol. 166, pp. 1825-1835 (December 1987)	
PB	18	DALE, James B., et al.; "Sequence of Myosin-Crossreactive Epitopes of Streptococcal M Protein," The Journal of Experimental Medicine, Vol. 164, pp. 1785-1790 (November 1986)	
PB	19	WANNAMAKER, Lewis W. M.D.; "Differences Between Streptococcal Infections of the Throat and of the Skin," The New England Journal of Medicine, Vol. 282, No. 1, pp. 23-30 (Jan. 1970)	
PB	20	KRUMWIEDE, Etma; "Studies on a Lipoproteinase of Group A Streptococci," The Journal of Experimental Medicine, Vol. 100, pp. 629-639 (1954)	

Examiner		Date	07/07/2006
Signature	/Padmavathi Baskar/	Considered	07/07/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08 (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

					Complete if Known	
Substitute for for				Application Number	10/771,931	
	MATION DIS			Filing Date	February 4, 2004	
SIAIE	STATEMENT BY APPLICANT			First Named Inventor	Harry S. COURTNEY	
	(use as many sheets	as necessary)		Art Unit	1645	
				Examiner Name	BASKAGE	
Sheet	3	of	3	Attorney Docket Number	13314.1001U	

	U.S. PATENT DOCMENTS								
Examiner Initials*	Cite No.1	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
	1	us-							
	2	US-							
	3	US-							
	4	us-							
	5	us-							

FOREIGN PATENT DOCUMENTS									
Cite No.1	Foreign Patent Oocument Country code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T⁰				
1									
2					1				
3									

OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²			
21	WARD, Hugh K., et al.; "Studies on Haemolytic Streptococci from Human Sources," The Australian Journal of Experimental Biology and Medical Science, Vol. 16, pp. 180-192 (1938)				
		<u> </u>			
		-			
	No.1	Cite No. 1 Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published 21 WARD, Hugh K., et al.; "Studies on Haemolytic Streptococci from Human Sources," The Australian Journal of Experimental Biology and Medical Science, Vol. 16, pp. 180-192 (1938)			

Examiner Signature	/Padmavathi Baskar/	Date Considered	07/07/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the Individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/S8/08 (10-01)

Approved for use through 10/31/2002, OMB 0651-0031

U.S. Patent and Tradsmark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete If Known		
				Application Number	10/771,931	
	INFORMATION DISCLOSURE STATEMENT BY APPLICANT			Filing Date	February 4, 2004	
				First Named Inventor	Harry S. COURTNEY	
				Art Unit	1614	
				Examiner Name		
Sheet	1	af	1	Attorney Dockel Number	13314.1001U	

			U.S. PAT	ent docments	
Examiner Initela*	Cite No.1	Document Number Number-Kind Code ¹ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear
PB	1	US-6,419,932 B1	July 16, 2002	Dal	
PB	2	US-5,707,822	January 13, 1998	Fischetti, et al.	
	3	us-			
	4	ม ร-		The second of th	.,.
	5	US-			
	6	บร-			
	7	US-			
	8	us-			
	9	us-			
-	10	US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.'	Foreign Patent Document Country code ³ -Number ⁶ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	TO		
	1				1 40.00 / 40.001	\vdash		
	2					 		
	3				· · · · · · · · · · · · · · · · · · ·	 		
	_ 4				· · · · · · · · · · · · · · · · · · ·	 		
	5				· · · · · · · · · · · · · · · · · · ·	\vdash		

	OTHER PRIOR ARY — NON PATENT LITERATURE DOCUMENTS					
Exeminer Initials	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, sandal, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	73			
	,					
	2					
	3		T			
	4		\top			
	5	•				

Examiner Signature	/Padmavathi Baskar/	Date Considered	07/07/2006

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw tine through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique cliation designation number (options). ² See Kinds Codes of USPTO Patent Documents at <u>www.usplo.gov.</u> or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must proceed the serial number of the patent document. ³ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁴ Applicant is to place a check mark here if English language Transfation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents, Washington, DC 20231,